跳到正文
原文
PharmaTimes· John Pinching·· 22 天前精选AI 评分70

Hutchmed 公布 SANOVO III 期结果:ORPATHYS 联合 TAGRISSO 一线治疗 EGFR 突变伴 MET 过表达非小细胞肺癌

Hutchmed reports phase 3 SANOVO data for first‑line lung cancer

AI 导读

Hutchmed 公布 SANOVO III 期结果,ORPATHYS(savolitinib)联合 TAGRISSO(osimertinib)用于初治的 EGFR 突变伴 MET 过表达非小细胞肺癌,意向治疗人群中位 PFS 为 24.9 个月,TAGRISSO 单药为 13.8 个月,疾病进展或死亡风险降低 44%。

推荐理由

III 期 SANOVO 同时给出意向治疗与高 MET 亚组的 PFS、OS 分层数据,便于对照现有 EGFR-TKI 单药一线方案。

正文 · 原文

Combination shows strong PFS and OS gains in MET‑overexpressing EGFRm disease

Hutchmed has announced positive phase 3 results from the SANOVO trial evaluating ORPATHYS plus TAGRISSO in treatment‑naïve patients with EGFR‑mutated non‑small cell lung cancer and MET overexpression. The data, presented at ESMO Congress 2026, showed statistically significant and clinically meaningful improvements in progression‑free survival compared with TAGRISSO alone.

Professor Yi‑Long Wu said: “The SANOVO results mark a pivotal evolution in how we approach first-line EGFR-mutated lung cancer. Historically, co-occurring MET alterations have been associated with poor outcomes on EGFR-TKI treatment, increasing the motivation to test for MET alterations at diagnosis and upon progression.

These potentially practice-changing results showed that adding savolitinib to osimertinib extended median PFS by more than a year in the high MET population, and 11 months overall, in first-line MET-overexpressing EGFR-mutated lung cancer.

“Coupled with highly encouraging clinical benefit in OS, these data reinforce the transformative potential of this all-oral, biomarker-directed treatment approach for a patient population where co-occurring MET overexpression may limit the long-term benefits of EGFR-TKI monotherapy.”

In the intention‑to‑treat population, the combination reduced the risk of disease progression or death by 44%, with median PFS reaching 24.9 months versus 13.8 months for TAGRISSO alone. In the high MET subgroup, risk reduction reached 55%, with median PFS of 24.8 months compared with 11.1 months. Overall survival also improved, with median OS of 44.5 months versus 34.9 months and three‑year survival rates of 67.4% versus 47.4%.

Mr Johnny Cheng, Acting Chief Executive Officer and Chief Financial Officer of Hutchmed, said: “SANOVO, alongside the SAFFRON and SACHI studies, establishes a comprehensive treatment continuum for the ORPATHYS plus TAGRISSO combination – spanning frontline intervention to post-EGFR-TKI resistance.

“SANOVO demonstrates that by identifying MET overexpression at diagnosis and initiating an all oral, dual-targeted combination upfront, we can meaningfully extend PFS and OS while preserving patient quality of life.”

来源:PharmaTimes · pharmatimes.com